Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Lance Armstrong's Oprah interview: Again with the cancer card
http://blog.nj.com/njv_kathleen_obrien/2013/01/lance_and_oprah.htmlLance Armstrong's Oprah interview: Again with the cancer card
By Kathleen O'Brien/The Star-Ledger
... Hed always been a competitor, he said. But after cancer which he several times called the disease he became a fierce competitor, willing to do whatever he had to do to survive.
That process turned me into a person who was truly win at all costs, he said. And I took that ruthless and relentless, win at all cost attitude right into cycling.
There it was: the cancer card, subtly played. It seemed to make a lot of sense .a life-altering event that propels one down a different path.
Until Oprah smoothly noted, But you had already been doing drugs before that. ...
-----------------------------------------------------------------------------------------
http://www.latimes.com/entertainment/tv/showtracker/la-et-st-lance-armstrong-oprah-cancer-bully-20130117,0,5979142.story
Lance Armstrong tells Oprah that cancer battle made him a 'bully'
By Patrick Kevin Day
Lance Armstrong admitted to Oprah Winfrey during his televised interview on OWN that in the course of defending himself from charges that he'd used banned substances in his cycling, he became a "bully." And surprisingly, he attributed it to his battle with testicular cancer that changed his attitude.
"I was always a fighter," Armstrong said in the first of the two-part interview that aired Thursday night. "Before my diagnosis, I was a competitor, but not a fierce competitor. Then I said I will do anything I need to do to survive. Then I brought that ruthless, win-at-all-costs attitude into cycling."
Winfrey brought up some of the people from Armstrong's past who had made allegations against the cycling star, people whom Armstrong had sued in retaliation for their claims against him. Among them was Betsy Andreu, wife of Armstrong's former teammate Frankie Andreu, one of the first people to go public with allegations that Armstrong had once admitted to using banned substances....
InfoView thread info, including edit history
TrashPut this thread in your Trash Can (My DU » Trash Can)
BookmarkAdd this thread to your Bookmarks (My DU » Bookmarks)
4 replies, 1634 views
ShareGet links to this post and/or share on social media
AlertAlert this post for a rule violation
PowersThere are no powers you can use on this post
EditCannot edit other people's posts
ReplyReply to this post
EditCannot edit other people's posts
Rec (1)
ReplyReply to this post
4 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
Lance Armstrong's Oprah interview: Again with the cancer card (Original Post)
jsr
Jan 2013
OP
graham4anything
(11,464 posts)1. Most likely, the steroids caused the cancer. Armstrong is a fraud.
using women and kids and charity to shield himself like a terrorist does.
Ash_F
(5,861 posts)2. Man...wouldn't that be a lesson.
Scootaloo
(25,699 posts)3. That's a bit much...
"using women and kids and charity to shield himself like a terrorist does."
I'd put egocentrism on a vastly different scale than terrorism, myself...
2on2u
(1,843 posts)4. Possibly, but it hasn't been confirmed, at least not yet if I read this right...
http://www.ncbi.nlm.nih.gov/pubmed/20890867
[Doping and urologic tumors].
[Article in Italian]
Pinto F, Sacco E, Volpe A, Gardi M, Totaro A, Calarco A, Racioppi M, Gulino G, D'Addessi A, Bassi PF.
Source
Clinica Urologica, Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma. francesco.pinto@libero.it
Abstract
Several substances such as growth hormone (GH), erythropoietin (Epo), and anabolic steroids (AS) are improperly utilized to increase the performance of athletes. Evaluating the potential cancer risk associated with doping agents is difficult since these drugs are often used at very high doses and in combination with other licit or illicit drugs. The GH, via its mediator, the insulin-like growth factor 1 (IGF-1), is involved in the development and progression of cancer.
Animal studies suggested that high levels of GH/IGF-1 increase progression of androgen-independent prostate cancer. Clinical data regarding prostate cancer are mostly based on epidemiological studies or indirect data such as IGF-1 high levels in patients with prostate cancer.
Even if experimental studies showed a correlation between Epo and cancer, no clinical data are currently available on cancer development related to Epo as a doping agent. Androgens are involved in prostate carcinogenesis modulating genes that regulate cell proliferation, apoptosis and angiogenesis.
Most information on AS is anecdotal (case reports on prostate, kidney and testicular cancers). Prospective epidemiologic studies failed to support the hypothesis that circulating androgens are positively associated with prostate cancer risk. Currently, clinical and epidemiological studies supporting association between doping and urological neoplasias are not available.
Nowadays, exposure to doping agents starts more prematurely with a consequent longer exposition period; drugs are often used at very high doses and in combination with other licit or illicit drugs. Due to all these elements it is impossible to predict all the side effects, including cancer; more detailed studies are therefore necessary.
[Doping and urologic tumors].
[Article in Italian]
Pinto F, Sacco E, Volpe A, Gardi M, Totaro A, Calarco A, Racioppi M, Gulino G, D'Addessi A, Bassi PF.
Source
Clinica Urologica, Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma. francesco.pinto@libero.it
Abstract
Several substances such as growth hormone (GH), erythropoietin (Epo), and anabolic steroids (AS) are improperly utilized to increase the performance of athletes. Evaluating the potential cancer risk associated with doping agents is difficult since these drugs are often used at very high doses and in combination with other licit or illicit drugs. The GH, via its mediator, the insulin-like growth factor 1 (IGF-1), is involved in the development and progression of cancer.
Animal studies suggested that high levels of GH/IGF-1 increase progression of androgen-independent prostate cancer. Clinical data regarding prostate cancer are mostly based on epidemiological studies or indirect data such as IGF-1 high levels in patients with prostate cancer.
Even if experimental studies showed a correlation between Epo and cancer, no clinical data are currently available on cancer development related to Epo as a doping agent. Androgens are involved in prostate carcinogenesis modulating genes that regulate cell proliferation, apoptosis and angiogenesis.
Most information on AS is anecdotal (case reports on prostate, kidney and testicular cancers). Prospective epidemiologic studies failed to support the hypothesis that circulating androgens are positively associated with prostate cancer risk. Currently, clinical and epidemiological studies supporting association between doping and urological neoplasias are not available.
Nowadays, exposure to doping agents starts more prematurely with a consequent longer exposition period; drugs are often used at very high doses and in combination with other licit or illicit drugs. Due to all these elements it is impossible to predict all the side effects, including cancer; more detailed studies are therefore necessary.